TTrialPathMatch Me to Trials
← Back to study

Eligibility check

First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Step 1 of 5

Where are you located?

We confirm your state so we only show studies you can actually reach.

Your answers help match you to studies and connect you with the research team. They're handled per our Privacy Policy.